These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29250133)

  • 1. Periodically Pulsed Immunotherapy in a Mathematical Model of Tumor, CD4
    Wei HC; Yu JL; Hsu CY
    Comput Math Methods Med; 2017; 2017():2906282. PubMed ID: 29250133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mathematical Modelling for the Role of CD4
    Makhlouf AM; El-Shennawy L; Elkaranshawy HA
    Comput Math Methods Med; 2020; 2020():7187602. PubMed ID: 32148558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal treatment strategy for a tumor model under immune suppression.
    Kim KS; Cho G; Jung IH
    Comput Math Methods Med; 2014; 2014():206287. PubMed ID: 25140193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An efficient methods for the induction of human antitumor effector CD4+ and CD8+ T cells: their application to tumor immunotherapy].
    Nishimura T; Kuge S; Watanabe K; Lee U; Yahata T; Habu S
    Hum Cell; 1994 Sep; 7(3):131-7. PubMed ID: 7873496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of In Vivo Antitumor Immunity with Hollow Mesoporous Silica Nanospheres.
    Wang X; Li X; Ito A; Watanabe Y; Sogo Y; Tsuji NM; Ohno T
    Angew Chem Int Ed Engl; 2016 Jan; 55(5):1899-903. PubMed ID: 26404897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations.
    de Pillis LG; Gu W; Radunskaya AE
    J Theor Biol; 2006 Feb; 238(4):841-62. PubMed ID: 16153659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical model for IL-2-based cancer immunotherapy.
    Dixon M; Phan TA; Dallon JC; Tian JP
    Math Biosci; 2024 Jun; 372():109187. PubMed ID: 38575057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.
    Yu P; Lee Y; Liu W; Krausz T; Chong A; Schreiber H; Fu YX
    J Exp Med; 2005 Mar; 201(5):779-91. PubMed ID: 15753211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deciphering CD4
    Kirkpatrick C; Lu YW
    Mol Carcinog; 2024 Jul; 63(7):1209-1220. PubMed ID: 38725218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.
    Ding ZC; Zhou G
    Clin Dev Immunol; 2012; 2012():890178. PubMed ID: 22400040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes.
    Klevorn LE; Berrien-Elliott MM; Yuan J; Kuehm LM; Felock GD; Crowe SA; Teague RM
    Cancer Immunol Res; 2016 Dec; 4(12):1016-1026. PubMed ID: 27803062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.
    Frangione V; Mortara L; Castellani P; De Lerma Barbaro A; Accolla RS
    Int J Cancer; 2010 Oct; 127(7):1614-24. PubMed ID: 20091859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin (IL)-24 transforms the tumor microenvironment and induces anticancer immunity in a murine model of colon cancer.
    Ma YF; Ren Y; Wu CJ; Zhao XH; Xu H; Wu DZ; Xu J; Zhang XL; Ji Y
    Mol Immunol; 2016 Jul; 75():11-20. PubMed ID: 27209087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.
    Arina A; Karrison T; Galka E; Schreiber K; Weichselbaum RR; Schreiber H
    Cancer Immunol Res; 2017 Feb; 5(2):127-136. PubMed ID: 28077434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
    Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.